Method for increasing expression level of exosomes from umbilical cord mesenchymal stem cells

By culturing umbilical cord mesenchymal stem cells under normal oxygen to low oxygen conditions in a 3D bioreactor, the problem of low exosome secretion of umbilical cord mesenchymal stem cells was solved, and the significant increase in exosome expression was achieved and Adaptability of industrial production.

WO2024250511A1PCT designated stage expired Publication Date: 2024-12-12TINGO EXOSOMES TECH CO LTD

Patent Information

Application Number
PCT/CN2023/124398
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-05
Filing Date
2023-10-13
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

When umbilical cord mesenchymal stem cells are cultured without serum under normal oxygen conditions in 3D environment, the secretion of exosomes is low, which limits the promotion and application of their biological products. In vitro 2D culture has safety risks and large-scale culture limitations.

Method used

Human umbilical cord mesenchymal stem cells are cultured in a 3D bioreactor with variable dissolved oxygen conditions. First, normal oxygen and then low oxygen. The normal oxygen partial pressure is controlled to 50%, and the low oxygen partial pressure is between 15-25%. Exosomes were harvested and purified by 3D bioreactor.

Benefits of technology

It significantly increases the expression of exosomes of mesenchymal stem cells in umbilical cord, is suitable for mass production, and promotes the industrial production of biological products of umbilical cord-derived mesenchymal stem cell exosomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023124398_12122024_PF_FP_ABST
    Figure CN2023124398_12122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a method for increasing the expression level of exosomes from human umbilical cord mesenchymal stem cells, comprising: inoculating human umbilical cord mesenchymal stem cells into a 3D bioreactor with a variable dissolved oxygen condition, wherein the dissolved oxygen condition is to switch from normoxic culture to hypoxic culture, the oxygen partial pressure in a normoxic condition is controlled to be 50%, and the oxygen partial pressure in a hypoxic condition is controlled to be 15%. The beneficial effects are that: the expression level of exosomes from umbilical cord mesenchymal stem cells cultured under a normoxic to hypoxic condition in a 3D bioreactor is obviously higher than that under normoxic, hypoxic, and hypoxic to normoxic conditions; and the present invention is suitable for mass production and is easy to promote industrial production of umbilical cord mesenchymal stem cell-derived exosome biological products.
Need to check novelty before this filing date? Find Prior Art

Description

A method for increasing the expression of exosomes from umbilical cord mesenchymal stem cells Technical Field

[0001] The present invention belongs to the technical field of human umbilical cord mesenchymal stem cell culture methods, and relates to a method for increasing the expression level of exosomes in umbilical cord mesenchymal stem cells. Background Art

[0002] Umbilical cord mesenchymal stem cells refer to a type of multifunctional stem cells present in the umbilical cord tissue of newborns. They are derived from the mesoderm and have high self-renewal and multidirectional differentiation capabilities, and therefore have broad clinical application prospects.

[0003] Exosomes are small, saucer-shaped vesicles with a diameter between 30 and 150 nm that contain RNA, microRNA, proteins, and DNA fragments. Almost all cells in the human body can secrete exosomes, and they are naturally present in body fluids, including saliva, urine, cerebrospinal fluid, blood, and breast milk. Umbilical cord mesenchymal stem cells are no exception, secreting exosomes under both normal and pathological conditions. Exosomes are primarily derived from multivesicular bodies formed by the invagination of intracellular lysosomal microparticles. They are released into the extracellular matrix after the outer membrane of the multivesicular body fuses with the cell membrane. Compared to umbilical cord mesenchymal stem cells, exosomes contain maternal-derived proteins, lipids, and nucleic acids. Their small molecular weight and high permeability allow them to act as signaling molecules on other cells.

[0004] Currently, umbilical cord mesenchymal stem cells are primarily cultured in a 2D model in vitro, cultured in complete (serum) culture medium at normoxic concentrations. This complete culture medium typically contains animal serum components, which may contain some unknown allergens and pathogens. This makes the exosomes produced during the cell culture process a significant safety risk, and large-scale culture under 2D conditions has significant limitations. However, umbilical cord mesenchymal stem cells cultured in serum-free culture medium under normoxic conditions in a 3D environment have better adherent growth and higher cell activity, but the exosome secretion is low, limiting the promotion and application of umbilical cord-derived mesenchymal stem cell exosome bioproducts.

[0005] Summary of the Invention

[0006] To solve the above technical problems, the present invention provides a method for increasing the expression level of exosomes from umbilical cord mesenchymal stem cells.

[0007] The technical solution adopted by the present invention is: a method for increasing the expression of exosomes in umbilical cord mesenchymal stem cells, inoculating human umbilical cord mesenchymal stem cells into a 3D bioreactor with variable dissolved oxygen conditions, wherein the dissolved oxygen conditions are converted from normoxia to hypoxia culture.

[0008] Preferably, the oxygen partial pressure is controlled at 50% under normoxic conditions and at 15-25% under hypoxic conditions.

[0009] Preferably, the specific steps are as follows:

[0010] Culture and expand primary human umbilical cord mesenchymal stem cells;

[0011] Human umbilical cord mesenchymal stem cells were seeded into a 3D bioreactor containing microcarriers and cultured in normoxia for 48-72 hours, followed by hypoxia for 48-72 hours.

[0012] After the culture is completed, the cell culture supernatant is harvested and separated and purified to obtain human umbilical cord mesenchymal stem cell exosomes. Preferably, the primary human umbilical cord mesenchymal stem cells are revived, passaged, and expanded.

[0013] Preferably, the 3D bioreactor culture carrier uses Cytodex 1 microcarrier with an inoculation concentration of 2.5 g / mL and a cell inoculation density of 1.6×10 5 cells / mL.

[0014] Preferably, in the 3D bioreactor culture, the optimal pH value is 7.3±0.1, the stirring speed is 60-80 rpm, the ventilation volume is set to 0.03-0.1 slpm, the perfusion inflow rate is 1 mL / min, and the perfusion outflow rate is 1 mL / min.

[0015] Exosomes are prepared by a method for increasing the expression level of exosomes from umbilical cord mesenchymal stem cells.

[0016] The present invention has the following beneficial effects: the expression level of umbilical cord mesenchymal stem cell exosomes cultured under normoxia-hypoxia conditions in a 3D bioreactor is significantly increased compared with normoxia, hypoxia, and hypoxia-normoxia conditions; it is suitable for batch production and can easily promote the industrial production of umbilical cord-derived mesenchymal stem cell exosome bioproducts. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 shows the growth morphology of hMSCs attached to microcarriers; Scale bar = 100 μm;

[0018] Figure 2 is the hMSCs cell growth curve;

[0019] Figure 3 shows the measurement of cell growth and metabolism by a fully automatic biochemical analyzer;

[0020] Figure 4 shows the expression of exosome surface markers in cell supernatants determined by Elisa;

[0021] Figure 5 shows the identification of exosome morphological characteristics;

[0022] Figure 6 shows the number of exosome particles determined by nanoflow cytometry;

[0023] Figure 7 shows the determination of exosome protein concentration by BCA method. DETAILED DESCRIPTION

[0024] The embodiments of the present invention are described below with reference to the accompanying drawings.

[0025] The present invention discloses a method for increasing the expression of exosomes in umbilical cord mesenchymal stem cells. The mesenchymal stem cells are seeded in a 3D environment and cultured first under normoxic conditions and then under hypoxic conditions. The oxygen partial pressure in normoxic conditions is controlled at 50%, and the oxygen partial pressure in hypoxic conditions is controlled at 15-25%. The details are as follows:

[0026] Step 1: First, take the cells from the umbilical cord mesenchymal stem cell working cell bank for recovery, and use the conventional cell recovery method in the field to culture the seed cells required for the 3D bioreactor under 2D conditions; in certain embodiments of the present invention, specifically, the umbilical cord-derived mesenchymal stem cells are inoculated into a T175 culture flask at a seeding density of 10,000 to 14,000 cells / mL, and cultured at 37°C and 5% CO2. The complete culture medium is a mesenchymal stem cell basal culture medium supplemented with a serum-free culture medium additive.

[0027] Step 2: The seed cells are then inoculated into a 3D environment and cultured under normoxia for 48-72 hours. After 48-72 hours, the dissolved oxygen (DO) is adjusted and the cells are cultured under hypoxic conditions for another 48-72 hours. During the culture process, the perfusion volume is determined based on biochemical parameters, and the corresponding supernatant is harvested for ultracentrifugation to collect exosomes. The 3D conditions are provided by a bioreactor; the bioreactor is a fully enclosed, fully automated system that controls pH, temperature, pressure, DO (deep aeration), liquid level, stirring speed, and defoaming. Daily monitoring of hMSCs cultured in the bioreactor is performed by sampling from a sampling port, and a fully automated biochemical analyzer measures biochemical parameters such as glucose, lactate, glutamine, and glutamate.

[0028] Before inoculating the seed cells into the 3D environment, they are first tested, including phenotypic testing and microbial safety testing; the phenotypic testing is to test the mesenchymal stem phenotype of the seed cells, and CD73, CD90, CD105 ≥ 95%, CD11b, CD19, CD34, CD45, HLA-DR ≤ 2% are qualified umbilical cord mesenchymal stem cells; the microbial safety testing is to test the sterility and mycoplasma microbial safety of the seed cell culture supernatant, and it meets the requirements of sterility negative and mycoplasma negative.

[0029] The cell attachment carrier in the bioreactor is Cytodex 1. The surface area of ​​Cytodex 1 microcarriers is 4400 cm 2 / g, each gram contains about 4.3×10 6The bioreactor was designed for a 2.5 g / L Cytodex 1 microcarrier with an expansion factor of 20 mL / g. The inoculum concentration was 2.5 g / L for Cytodex 1 microcarriers and 15 cells / ball. The optimal pH in the bioreactor was 7.3 ± 0.1, the optimal stirring speed was 60-80 rpm, the culture temperature was preferably 37°C, and the aeration rate was set at 0.03-0.1 slpm. When the biochemical monitoring values ​​in the bioreactor showed Gluc < 1 g / L and Glun < 0.1 g / L, complete culture medium was automatically perfused into the bioreactor at a rate of 1 mL / min, and the culture supernatant was simultaneously perfused and collected at the same rate.

[0030] During culture, the DO (DO) is 50% under normoxic conditions and 15-25% under hypoxic conditions. The oxygen partial pressure is achieved by introducing air, carbon dioxide, oxygen, and nitrogen into the culture medium in the bioreactor. Under hypoxic conditions, the air, carbon dioxide, oxygen, and nitrogen are treated by a gas distributor, resulting in a final oxygen partial pressure within the bioreactor of 15-25%. This oxygen content provides the basic conditions necessary for the growth and proliferation of umbilical cord mesenchymal stem cells cultured in the bioreactor and increases the expression of their exosomes.

[0031] After 72 hours of hypoxic culture in the bioreactor, the supernatant was tested for sterility and mycoplasma detection to monitor microbial safety, and the cells were also tested for phenotypic analysis. Daily monitoring was performed by sampling the bioreactor's sampling port. Biochemical parameters of the supernatant were measured, the supernatant was centrifuged and stored at -80°C, and the cells were digested with Tryple enzyme for cell counting.

[0032] After culture, umbilical cord mesenchymal stem cells cultured in the 3D bioreactor were sampled and digested from the Cytodex 1 microcarriers using Tryple digestion enzyme. Cell phenotype was assessed by flow cytometry. Cells were considered to meet the standard if CD73, CD90, and CD105 levels were ≥95% and CD11b, CD19, CD34, CD45, and HLA-DR levels were ≤2%. The cell culture supernatant was harvested and poured into a centrifuge cup, centrifuged at 2500g for 15 minutes, transferred to a sterile reagent bottle, and stored at -80°C. The collected supernatant was used to extract exosomes.

[0033] The present invention is described below with reference to the accompanying drawings. Experimental methods not specifically described were performed according to the corresponding commercial specifications. Instruments, reagents, and consumables used in the examples are commercially available unless otherwise specified. The bioreactor used in the examples is an SKC300 bioreactor developed by Wuhan Saikecheng Technology Co., Ltd.; the volume of the bioreactor used is 2.5 L. The biochemical analyzer used in the present invention is a fully automatic biochemical analyzer M-900 from Silman Technology Co., Ltd.

[0034] Example 1

[0035] In Example 1, human umbilical cord-derived mesenchymal stem cells were seeded in a 3D bioreactor. The hypoxic culture method of the cells included the following steps:

[0036] Primary human umbilical cord mesenchymal stem cells from the working cell bank were revived. The working bank cells were quickly transferred to a 37°C water bath and gently shaken to melt. In a clean bench, the cell cryopreservation solution was transferred to a centrifuge tube containing complete culture medium. After centrifugation at 400g for 5 minutes, the supernatant was discarded, and the cells were resuspended in an appropriate amount of complete culture medium. After thorough mixing, the cells were counted.

[0037] According to 1×10 per square centimeter 4 The cells were seeded at a density of 100 cells per well in a T175 cell culture flask. The culture flask containing the cells was placed in a 37°C, 5% CO2 incubator for continued culture. After the cell confluence reached 80%-90%, the cells were collected and passaged. hMSCs were subcultured under 2D conditions to the required number of seed cells for the 3D bioreactor. The complete culture medium was serum-free mesenchymal stem cell medium.

[0038] Seed cells were inoculated into a 3D bioreactor using Cytodex 1 microcarriers at a concentration of 2.5 g / L and 15 cells / ball. Cells were then inoculated into a 2.5 L bioreactor using a 1.5 L culture system. Cultures were performed under normoxia for 48 hours and then under hypoxia for 72 hours. The DO was maintained at 50% under normoxia and 15% under hypoxia.

[0039] In this embodiment, the optimal pH value within the bioreactor is 7.3±0.1, the optimal stirring speed is 80 rpm, the culture temperature is preferably 37°C, the ventilation rate is set to 0.03-0.1 slpm, and the oxygen partial pressure is controlled at 50% under normoxic conditions for 48 hours of cell culture. Under hypoxic conditions, the oxygen partial pressure is controlled at 15% for 72 hours of cell culture. The above-mentioned oxygen partial pressure regulation is achieved by introducing air, carbon dioxide, oxygen, and nitrogen into the culture medium in the bioreactor. Under hypoxic conditions, the air, carbon dioxide, oxygen, and nitrogen are treated by a gas sparger, and the final oxygen partial pressures within the bioreactor are controlled at 50% and 15%, respectively. Daily monitoring samples of cell culture were taken from the one-way sampling port of the bioreactor. The samples were tested for biochemical indicators such as glucose, lactate, and glutamine using a fully automatic biochemical analyzer. When the biochemical monitoring values ​​in the bioreactor showed that Gluc was less than 1 g / L and Gln was less than 0.1 g / L, complete culture medium was automatically perfused into the bioreactor at a rate of 1 mL / min. At the same time, the culture supernatant in the bioreactor was perfused and collected at the same rate. After the perfusion culture was completed, samples were taken to detect the exosome content in the cell culture supernatant.

[0040] Comparative Example

[0041] The comparative examples include three, in which seed cells were inoculated in a 3D bioreactor. The difference from Example 1 lies in the culture conditions. The three comparative examples are: cells were cultured in normoxia for 120 h, with the oxygen partial pressure under normoxia controlled at 50%; cells were cultured in hypoxia for 120 h, with the oxygen partial pressure under hypoxia controlled at 15%; cells were cultured in hypoxia for 48 h and then switched to normoxia for a further 72 h, with the oxygen partial pressure under hypoxia controlled at 15% and the oxygen partial pressure under normoxia controlled at 50%.

[0042] The culture conditions of the examples and comparative examples are shown in Table 1;

[0043] Table 1

[0044] After the perfusion culture of the three control groups was completed, samples were taken to detect the exosome content in the cell culture supernatant.

[0045] Example 2: Performance testing experiment

[0046] Before seed cells are inoculated into the 3D bioreactor, they are tested, including phenotypic testing and microbial safety testing: P8 cells are tested for mesenchymal stem cell phenotype, and CD73, CD90, and CD105 are all ≥95%, and CD11b, CD19, CD34, CD45, and HLA-DR are all ≤2% to qualify as umbilical cord mesenchymal stem cells; microbial safety testing involves sterility and mycoplasma testing of the P8 cell culture supernatant, which meets the requirements of sterility negative and mycoplasma negative.

[0047] Daily monitoring samples of bioreactor cell culture were taken from the one-way sampling port, and the biochemical indexes of the cell supernatant were measured. The cell supernatant was centrifuged at 300g for 5 minutes and then stored at -80℃. The expression of exosome surface markers was measured by Elisa. The growth of hMSCs cells attached to Cytodex 1 microcarriers was observed under an inverted microscope.

[0048] The Cytodex 1 microcarriers attached with hMSCs were digested with Tryple digestion enzyme and the cells were counted.

[0049] After 120 hours of 3D bioreactor culture, cell culture samples were terminated and phenotypic analysis was performed. Cell culture supernatants were harvested and analyzed for cell surface antigens including CD73, CD90, CD105, CD11b, CD19, CD34, CD45, and HLA-DR. Cells were considered to meet the standards if CD73, CD90, and CD105 were ≥95% and CD11b, CD19, CD34, CD45, and HLA-DR were ≤2%. Prior to purification, cell culture supernatant samples were tested for sterility and mycoplasma microbiological safety. Purification of the cell culture supernatant was initiated only after sterility and mycoplasma-negative results were obtained. hMSCs-exo cells were isolated and purified, and their morphology was determined by transmission electron microscopy, particle count by nanoflow cytometry, and protein concentration by BCA assay.

[0050] As shown in Figure 1, the morphology of hMSC cells cultured in a 3D bioreactor, A is the normoxia cell group (Comparative Example 1), B is the normoxia-to-hypoxia cell group (Example 1), C is the hypoxia cell group (Comparative Example 2), and D is the hypoxia-to-normoxia cell group (Comparative Example 3). The hMSCs cells in groups AB are in good adherent growth state, the cells are evenly attached to the surface of the microcarrier balls, and the cells are long spindle-shaped. There is no obvious difference in the cell growth state between the two groups; this proves that the normoxia-to-hypoxia culture process has no effect on the cell shape; the hMSCs cells in group CD are partially attached to the surface of the microcarrier balls and grow in a long spindle shape, but most of the cells are free in the cell suspension.

[0051] Figure 2 shows the growth curves of hMSCs cultured in a 3D bioreactor. The 50% group represents normoxia, the 50%-15% group represents normoxia-to-hypoxia, the 15% group represents hypoxia, and the 15%-50% group represents hypoxia-to-normoxia. As shown in the figure, the 50% and 50%-15% groups had similar cell growth rates from 0 to 48 hours, and similar cell growth trends from 48 to 120 hours, but the cell density in the 50%-15% group was slightly higher than that in the 50% group. The 15% and 15%-50% groups had similar cell growth rates from 0 to 48 hours, and similar cell growth trends from 48 to 120 hours, but the cell density in the 15% group was slightly higher than that in the 15%-50% group. The cell density in the 50%-15% group was significantly higher than that in the 50%, 15%, and 15%-50% groups.

[0052] Figure 3 shows the growth and metabolic curves of hMSCs cultured in a 3D bioreactor, using the same experimental groups as above. Cell growth and metabolism in the 50% and 50%-15% groups were similar from 0 to 48 hours, with similar growth and metabolic trends between the two groups from 48 to 120 hours. Compared with the 50% group, the 50%-15% group showed significantly faster glucose consumption and lactate metabolism, but glutamine uptake decreased with prolonged culture time. This is primarily due to the ability of cells to meet their energy needs through anaerobic respiration under hypoxic conditions. Cell growth and metabolism in the 15% and 15%-50% groups were similar from 0 to 48 hours, with similar growth and metabolic trends between the two groups from 48 to 120 hours. Compared with the 15%-50% group, the 15% group showed significantly faster glucose consumption and lactate metabolism, while glutamine uptake decreased with prolonged culture time. The 50%-15% group showed significantly higher glucose consumption and lactate metabolism than the 50%, 15%, and 15%-50% groups.

[0053] Elisa was used to determine the expression of exosome surface markers in the cell supernatant. As shown in Figure 4, the expression levels of exosome surface markers CD81, CD9, and CD63 in the samples of the 50%-15% group were higher than those in the 50% group; the expression levels of exosome surface markers CD81, CD9, and CD63 in the samples of the 15% group were higher than those in the 15%-50% group; among them, the expression levels of exosome surface markers CD81, CD9, and CD63 in the samples of the 50%-15% group were significantly higher than those in the 50%, 15%, and 15%-50% groups.

[0054] The morphology of the purified samples was observed by transmission electron microscopy. As shown in Figure 5 , the morphology of the samples in the AD group all showed cup-shaped particles with a slightly concave center, which is consistent with the morphological characteristics of exosomes.

[0055] Nanoflow cytometry was used to statistically analyze the number of exosome particles in the samples, and the results are shown in Table 1 and Figure 6.

[0056] Table 1 Number of exosome particles in samples

[0057] As shown in Table 1, under the same initial culture conditions, after adjusting the oxygen partial pressure for 48 hours, the number of exosome particles in the hypoxic culture group was significantly higher than that in the group with the same initial culture conditions, with statistical significance. Nanoflow cytometry results showed that the 50%-15% group had a 47% higher number than the 50% group, the 50%-15% group had a 178% higher number than the 15% group, the 50%-15% group had a 232% higher number than the 15%-50% group, and the 15% group had a 20% higher number than the 15%-50% group. Compared with the other groups, the normoxia-hypoxia transition group promoted the secretion of cellular exosomes.

[0058] In addition, supernatants harvested under different culture conditions were purified using ultracentrifugation to prepare high-purity exosomes. The BCA assay was used to determine the exosome protein concentration in the samples. The results are shown in Table 2. The 50%-15% group showed a 37% increase compared to the 50% group, the 50%-15% group showed a 114% increase compared to the 15% group, the 50%-15% group showed a 178% increase compared to the 15%-50% group, and the 15% group showed a 30% increase compared to the 15%-50% group. Compared to the other groups, the normoxia-to-hypoxia group showed the highest exosome protein concentration, further demonstrating that lowering oxygen tension promotes exosome secretion and increases exosome expression in the cell supernatant.

[0059] Table 2 Sample exosome protein concentration

[0060] The embodiments of the present invention are described in detail above, but the contents described are only preferred embodiments of the present invention and should not be considered to limit the scope of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.

Claims

1. A method for increasing the expression of exosomes from umbilical cord mesenchymal stem cells, Features: Human umbilical cord mesenchymal stem cells were inoculated into a 3D bioreactor with variable dissolved oxygen conditions, and the dissolved oxygen conditions were changed from normoxia to hypoxia culture.

2. The method for increasing the expression of exosomes of umbilical cord mesenchymal stem cells according to claim 1, Features: The oxygen partial pressure in normoxic conditions is controlled at 50%, and that in hypoxia is between 15-25%.

3. The method for increasing the expression of exosomes of umbilical cord mesenchymal stem cells according to claim 1 or 2, Features: The specific steps are as follows: Cultivate and expand primary human umbilical cord mesenchymal stem cells; Human umbilical cord mesenchymal stem cells were inoculated into a 3D bioreactor containing microcarriers and cultured in normoxia for 48-72 hours, followed by hypoxia for 48-72 hours; After the culture was completed, the cell culture supernatant was harvested and separated and purified to obtain human umbilical cord mesenchymal stem cell exosomes.

4. The method for increasing the expression of exosomes of umbilical cord mesenchymal stem cells according to claim 3, Features: Primary human umbilical cord mesenchymal stem cells undergo recovery, passaging, and expansion steps.

5. The method for increasing the expression of exosomes of umbilical cord mesenchymal stem cells according to claim 3, Features: The 3D bioreactor culture carrier uses Cytodex 1 microcarriers with an inoculation concentration of 2.5 g / mL and a cell inoculation density of 1.6 × 10 5 cells / mL.

6. The method for increasing the expression of exosomes of umbilical cord mesenchymal stem cells according to claim 3, Features: For 3D bioreactor culture, the optimal pH value was 7.3±0.1, the stirring speed was 60-80rpm, the ventilation volume was set to 0.03-0.1slpm, the perfusion inflow rate was 1mL / min, and the perfusion outflow rate was 1mL / min.

7. Exosomes prepared by the method for increasing the expression of exosomes of umbilical cord mesenchymal stem cells according to any one of claims 1 to 6.

Citation Information

Patent Citations

  • Method for improving yield of mesenchymal stem cell exosomes

    CN109182259A

  • Culture method of low-oxygen umbilical cord mesenchymal stem cells

    CN115058391A

  • Human umbilical cord mesenchymal stem cell exosome as well as preparation method and application thereof

    CN115125198A

  • Method for efficiently producing umbilical cord mesenchymal stem cell-derived exosome

    CN115418349A

  • Method for efficient mass production of umbilical cord mesenchymal stem cell exosomes

    CN116103230A

Cited By

  • Panda immortalized kidney cell line GPK-1, preparation method and application

    CN119776258A